Bioregulators · Senolytics · Longevity

Best Peptides for Anti-Aging & Longevity

Russian bioregulators, senolytics, mitochondrial peptides, and the copper tripeptide. Decades of Khavinson research plus the new wave of senescent-cell clearance. Full longevity toolkit.

🔬 HighPeptides Editorial — Anti-aging is HighPeptides' premium-audience category — readers here tend to be well-read, evidence-driven, and willing to experiment. The coverage reflects that: Khavinson's Russian work + Western senolytics + mitochondrial peptides.
20+
Anti-Aging Research Pages
4
Mechanistic Categories
25+yrs
Khavinson Research Record

Common Combinations

Frequently Asked Questions

Where should I start with longevity peptides?

Start with GHK-Cu (widest evidence, topical or SC), add Epitalon for the telomerase/pineal axis, and consider adding fisetin as your senolytic. That three-compound foundation covers the main longevity mechanisms.

Is telomerase activation dangerous?

Theoretically yes — telomerase is upregulated in ~85% of cancers. Practically: Khavinson's clinical data spans 25+ years without excess cancer signal. Most protocols cycle (10-20 days on, 10-20 days off) rather than continuous dosing.

Fisetin or D+Q for senolytics?

Fisetin alone is the OTC option — simpler, safer, weaker. D+Q requires a prescription for dasatinib but has the strongest human data (Mayo Phase 2). Most users start with fisetin.

How often should I cycle?

Khavinson's original protocols use 10-20 day cycles with similar off-time, 2-3 cycles per year. Senolytics are monthly hit-and-run. GHK-Cu can be daily (especially topical). Mitochondrial peptides weekly.

🔬 Research-Grade Source

Swiss Chems stocks third-party HPLC-tested peptides with published COAs per batch. HighPeptides' primary vendor reference.

Browse Swiss Chems →

Affiliate link — supports HighPeptides at no extra cost

Key Takeaways

✅ What We Know
  • Epitalon re-activates telomerase in vitro — core longevity mechanism
  • GHK-Cu modulates ~4000 genes and has the widest evidence base
  • Senolytic intermittent dosing extends healthspan in mouse studies (D+Q)
  • Russian bioregulator clinical record spans 25+ years without major safety signal
  • Fisetin provides OTC senolytic access with real (though weaker) evidence
  • Mitochondrial peptides (MOTS-c, SS-31) represent emerging anti-aging frontier
⚠️ What We Don't Know
  • No large human RCT with mortality endpoints for any peptide in this category
  • Telomerase activation has theoretical cancer concern
  • Russian clinical data has limited Western replication
  • Long-term (decade+) human safety of repeated cycles is not rigorously characterized
  • Quality variance across vendors is high — third-party COAs are mandatory
⚠️ Disclaimer

Bioregulators and longevity peptides are research-use only. No compound on this page is FDA-approved as a longevity or anti-aging therapy.

Not medical advice. Always consult a qualified healthcare provider. Research use only.

ESC
🔍 Search peptides, guides, and research...
↑↓ navigate   open   esc close